Editorial: Genetics of familial hypercholesterolemia: New insight—Volume II

Editorial: Genetics of familial hypercholesterolemia: New insight—Volume II

Bibliographic Details
Main Authors:	Alpo Vuorio, Uma Ramaswami, Kirsten B. Holven
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Genetics
Subjects:	familial hypercholesterolemia mutations LDL Lp(a) statins PCSK9 inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2022.1041342/full

Similar Items

Editorial: Genetics of Familial Hypercholesterolemia: New Insight
by: Alpo Vuorio, et al.
Published: (2021-05-01)

Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia
by: Alpo Vuorio, et al.
Published: (2022-05-01)

Familial Hypercholesterolemia Patients with COVID-19—Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection
by: Alpo Vuorio, et al.
Published: (2022-12-01)

Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism
by: Alpo Vuorio, et al.
Published: (2021-10-01)

Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke
by: Alpo Vuorio, et al.
Published: (2021-06-01)

Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction
by: Petri T. Kovanen, et al.
Published: (2021-09-01)

Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community
by: Hayato Tada, et al.
Published: (2020-11-01)

Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation
by: Alpo Vuorio, et al.
Published: (2021-04-01)

Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied
by: Leo Ungar, et al.
Published: (2018-08-01)

Prevalence and Impact of Apolipoprotein E7 on LDL Cholesterol Among Patients With Familial Hypercholesterolemia
by: Hayato Tada, et al.
Published: (2021-04-01)

Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study
by: Kjell-Erik Arnesen, et al.
Published: (2021-03-01)

Case report: Unusual coexistence between familial hypercholesterolemia and familial hypobetalipoproteinemia
by: Kei Sasaki, et al.
Published: (2022-08-01)

Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia
by: Xian Lv, et al.
Published: (2023-10-01)

Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016-09-01)

The Importance of Arterial Stiffness Assessment in Patients with Familial Hypercholesterolemia
by: Beáta Kovács, et al.
Published: (2022-05-01)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
by: Isabella Sudano, et al.
Published: (2022-07-01)

Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
by: Nagham N. Hindi, et al.
Published: (2021-08-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries
by: Marcello Arca, et al.
Published: (2023-11-01)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
by: Chang-Wook Nam, et al.
Published: (2019-11-01)

Competing Genetic Traits and Their Influence on LDL Cholesterol Concentration in Familial Hypercholesterolemia
by: Christopher Song, MD, et al.
Published: (2024-01-01)

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
by: Alpo Vuorio, et al.
Published: (2023-12-01)

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
by: Tamio Teramoto, et al.
Published: (2017-06-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues
by: Gisle Langslet, et al.
Published: (2021-06-01)

New Trends and Therapies for Familial Hypercholesterolemia
by: Fahad Alnouri, et al.
Published: (2022-11-01)

The risk of various types of cardiovascular diseases in mutation positive familial hypercholesterolemia; a review
by: Anders Hovland, et al.
Published: (2022-12-01)

An Untargeted Lipidomic Analysis Reveals Depletion of Several Phospholipid Classes in Patients with Familial Hypercholesterolemia on Treatment with Evolocumab
by: Andrea Anesi, et al.
Published: (2021-12-01)

Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part II. Clinical Characteristics
by: Tereza Altschmiedova, et al.
Published: (2022-03-01)

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
by: Massimiliano Allevi, et al.
Published: (2023-06-01)

Treatment with PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Lowers Plasma Levels of Platelet-Activating Factor and Its Precursors: A Combined Metabolomic and Lipidomic Approach
by: Alessandro Di Minno, et al.
Published: (2021-08-01)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
by: Henry CA, et al.
Published: (2016-04-01)

Aorta of young and middle-aged heterozygous familial hypercholesterolemia patients shows no functional or morphological impairment assessed by MRI
by: Sami Soljanlahti, et al.
Published: (2008-08-01)

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
by: Arianna Toscano, et al.
Published: (2022-04-01)

Mutation Analysis of the LDL Receptor Gene in Indian Families with Familial Hypercholesterolemia
by: Suyamindra S Kulkarni
Published: (2011-09-01)

Identification of a novel LDLR p.Glu179Met variant in Thai families with familial hypercholesterolemia and response to treatment with PCSK9 inhibitor
by: Burabha Pussadhamma, et al.
Published: (2024-03-01)

Low-density lipoprotein cholesterol lowering treatment: the current approach
by: Irina Crismaru, et al.
Published: (2020-05-01)

Familial hypercholesterolemia revealed by multiple xanthomas
by: Nassiba Elouarradi, et al.
Published: (2018-05-01)

Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
by: Pisciotta Livia, et al.
Published: (2012-09-01)

Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial
by: Hong Tan, et al.
Published: (2023-02-01)